Vaccinex (NASDAQ:VCNX) Stock Price Down 0.2% – Time to Sell?

Vaccinex, Inc. (NASDAQ:VCNX) shares traded down 0.2% during trading on Monday. The stock traded as low as $1.0080 and last traded at $1.0080. Approximately 464 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 2,982 shares. The stock had previously closed at $1.01.

Vaccinex Trading Down 0.2%

The business has a fifty day simple moving average of $0.99 and a two-hundred day simple moving average of $1.02. The stock has a market cap of $2.62 million, a PE ratio of -0.02 and a beta of 1.10.

Vaccinex Company Profile

Vaccinex, Inc (NASDAQ:VCNX) is a clinical-stage biotechnology company developing antibody-based therapies for neurodegenerative diseases and cancer. The company uses its proprietary ActivMAb antibody-discovery platform to identify and develop monoclonal antibodies directed at challenging therapeutic targets.

Vaccinex’s lead product candidate is pepinemab, an antibody designed to inhibit semaphorin 4D (SEMA4D), a protein involved in immune regulation, inflammation, and tissue damage. The company has evaluated pepinemab in clinical studies involving conditions including Huntington’s disease, Alzheimer’s disease, multiple sclerosis, and certain cancers, with development focused on potential treatments for neurological and immuno-oncology indications.

Vaccinex is headquartered in Rochester, New York, and its programs are developed through clinical research collaborations and trials conducted in the United States and other locations.